NATURECELL CO.,LTD.
Financials
Valuation Metrics
NATURECELL CO.,LTD.'s Market Cap is ₩1.4T. At end of 2025 it was ₩1.4T. Ranked #251 of 2,436 in KR market (top 10%), #59 of 1,649 on KOSDAQ (top 4%), #27 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 12%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.41T KRW | KR#251/2,436 Sec#27/234 |
| Revenue | 20.72B KRW | KR#2,131/2,436 Sec#154/234 |
| Net Income | -2.74B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 86.75B KRW | KR#1,854/2,436 Sec#152/234 |
| Net Assets | 63.09B KRW | KR#1,712/2,436 Sec#147/234 |
| Employees | 91 | KR#1,698/2,436 Sec#132/234 |
| Value | ||
| P/B | 22.42x | KR#2,389/2,436 Sec#221/234 |
| P/S | 68.27x | KR#2,377/2,436 Sec#202/234 |
| FCF Yield | -1.16% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -4.34% | KR#1,727/2,436 Sec#126/234 |
| ROA | -3.16% | KR#1,777/2,436 Sec#131/234 |
| Op. Margin | -15.75% | KR#2,077/2,436 Sec#143/234 |
| Revenue Growth | -0.44% | KR#1,466/2,436 Sec#140/234 |
| Earnings Growth | -1018.42% | KR#1,695/2,436 Sec#115/234 |
| Financial Health | ||
| Debt Ratio | 137.50% | KR#984/2,436 Sec#114/234 |
| Total Debt | 17.00B KRW | KR#1,416/2,436 Sec#119/234 |
| FCF | -16.39B KRW | KR#1,848/2,436 Sec#172/234 |
| Cash | 28.34B KRW | KR#1,037/2,436 Sec#69/234 |
| Current Ratio | 1.94x | KR#989/2,436 Sec#113/234 |
| Performance | ||
| 1Y Return | -38.34% | KR#1,795/2,436 Sec#157/234 |
| 1M Return | -7.77% | KR#1,611/2,436 Sec#163/234 |
| From 52W High | -44.22% | KR#943/2,436 Sec#72/234 |
| 1Y MDD | -55.29% | KR#1,172/2,436 Sec#93/234 |
| Trading | ||
| Volume | 436,410 shares | KR#311/2,436 Sec#36/234 |
| Foreign Own. | 6.74% | KR#635/2,436 Sec#62/234 |
| Per Share | ||
| EPS | -43 KRW | KR—/2,436 Sec—/234 |
| BPS | 979 KRW | KR#2,287/2,436 Sec#206/234 |
Company Info
Established in 1971 and listed on KOSDAQ in 1992, the company changed its corporate name to Naturecell Co., Ltd. in 2013, and acquired 100% of Naturecell America in the US in 2022, incorporating it as a subsidiary. It focuses on the R&D and commercialization of treatments for rare and intractable diseases using autologous fat-derived stem cells, conducting overseas clinical trials. Additionally, it manufactures and sells stem cell culture medium cosmetics and vegan beverages. Naturecell is headquartered in Yeongdeungpo-gu, Seoul.